BN80927 in Patients With Advanced Malignant Solid Tumors

Inclusion Criteria: All included patients: * Gave their written (personally signed and dated) informed consent * had histologically or cytologically documented malignant solid tumour * had received no more than three prior chemotherapy regimens * had failed the standard therapy or had no option of an active standard therapy * had an estimated survival time of greater than 3 months (according to the investigator's assessment) * had a World Health Organisation (WHO) performance status score ≤1 * were free from other serious concurrent disease * had adequate bone marrow function * had adequate liver function * had adequate renal function * who were female and of child-bearing potential must have had a negative result in a pre-study pregnancy test β-human-chorionic-gonadotrophin (β-HCG). Exclusion Criteria: No patient included: * was pregnant or lactating * was unable and/or unwilling to comply fully with the protocol and the study instructions; * presented with any concomitant condition, which could compromise the objectives of the study * had received an investigational drug within 30 days prior to study entry or was scheduled to require concurrent treatment with an experimental drug or treatment during the study * had received chemotherapy or hormonotherapy within 4 weeks of study entry, or had received chemotherapy with nitrosoureas or mitomycin-C within 6 weeks of study entry * had received any extensive palliative or curative radiotherapy (no more than 35% of their active bone marrow) within 2 weeks of study entry, or had not fully recovered from such treatment * had previously received a bone marrow transplant (BMT) or peripheral blood progenitor cells (PBPC) * had clinical evidence of major organ failure or brain metastases.